4.6

CiteScore

2.2

Impact Factor
  • ISSN 1674-8301
  • CN 32-1810/R
Volume 30 Issue 6
Oct.  2016
Turn off MathJax
Article Contents
Abstract
Related Articles
Yu Zhu, Liangqin Pan, Ming Hong, Weixing Liu, Chun Qiao, Jianyong Li, Sixuan Qian. The combination therapy of imatinib and dasatinib achieves long-term molecular response in two imatinib-resistant and dasatinibintolerant patients with advanced chronic myeloid leukemia[J]. The Journal of Biomedical Research, 2016, 30(6): 525-528. DOI: 10.7555/JBR.30.20130172
Citation: Yu Zhu, Liangqin Pan, Ming Hong, Weixing Liu, Chun Qiao, Jianyong Li, Sixuan Qian. The combination therapy of imatinib and dasatinib achieves long-term molecular response in two imatinib-resistant and dasatinibintolerant patients with advanced chronic myeloid leukemia[J]. The Journal of Biomedical Research, 2016, 30(6): 525-528. DOI: 10.7555/JBR.30.20130172
shu

The combination therapy of imatinib and dasatinib achieves long-term molecular response in two imatinib-resistant and dasatinibintolerant patients with advanced chronic myeloid leukemia

  • Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China

Funds: 

the National Natural Science Foundation of the People’s Republic of China (No.81070437, 81270614 and 81300379), the National Science & Technology Pillar Program of China (No. 2008BAI61B01)

More Information
  • Received Date: November 07, 2013
  • Revised Date: March 26, 2014
    Graphical Abstract
    • Abstract
  • For patients with chronic myeloid leukemia (CML) failing imatinib therapy, second-generation tyrosine kinase inhibitors (TKIs) are recommended. Here, we describe two patients with advanced CML who failed imatinib therapy and did not tolerate the recommended dose of dasatinib, but then achieved a major molecular response with the combination of imatinib and dasatinib with no significant extramedullary toxicity. Our observations suggest that combination of TKIs may provide an additive/synergistic antileukemic effect.
    • FullText(HTML)
    • References (0)
    • Related Articles

  • Related Articles

    [1]Minqin Xu, Lihua Zhang, Lan Lin, Zhiyi Qiang, Wei Liu, Jian Yang. Cisplatin increases carboxylesterases through increasing PXR mediated by the decrease of DEC1[J]. The Journal of Biomedical Research, 2023, 37(6): 431-447. DOI: 10.7555/JBR.37.20230047
    [2]Yue Xiao, Yue Peng, Chi Zhang, Wei Liu, Kehan Wang, Jing Li. hucMSC-derived exosomes protect ovarian reserve and restore ovarian function in cisplatin treated mice[J]. The Journal of Biomedical Research, 2023, 37(5): 382-393. DOI: 10.7555/JBR.36.20220166
    [3]Haozhe Xu, Yiming Zhou, Jing Guo, Tao Ling, Yujie Xu, Ting Zhao, Chuanxin Shi, Zhongping Su, Qiang You. Elevated extracellular calcium ions accelerate the proliferation and migration of HepG2 cells and decrease cisplatin sensitivity[J]. The Journal of Biomedical Research, 2023, 37(5): 340-354. DOI: 10.7555/JBR.37.20230067
    [4]Li Wanlin, Wu Min, Wang Qianqian, Xu Kun, Lin Fan, Wang Qianghu, Guo Renhua. A comparative genomics analysis of lung adenocarcinoma for Chinese population by using panel of recurrent mutations[J]. The Journal of Biomedical Research, 2021, 35(1): 11-20. DOI: 10.7555/JBR.34.20200068
    [5]Liu Shuying, Lu Shan. Antibody responses in COVID-19 patients[J]. The Journal of Biomedical Research, 2020, 34(6): 410-415. DOI: 10.7555/JBR.34.20200134
    [6]Zhu Ping, Shan Xia, Liu Jinhui, Zhou Xin, Zhang Huo, Wang Tongshan, Wu Jianqing, Zhu Wei, Liu Ping. miR-3622b-5p regulates cisplatin resistance of human gastric cancer cell line by targeting BIRC5[J]. The Journal of Biomedical Research, 2019, 33(6): 382-390. DOI: 10.7555/JBR.33.20180078
    [7]Aixia Zhang, Brian Cao. Generation and characterization of an anti-GP73 monoclonal antibody for immunoblotting and sandwich ELISA[J]. The Journal of Biomedical Research, 2012, 26(6): 467-473. DOI: 10.7555/JBR.26.20120057
    [8]Xinjian Liu, Xiaomin Feng, Qi Tang, Zhongcan Wang, Zhenning Qiu, Yuhua Li, Changjun Wang, Zhenqing Feng, Jin Zhu, Xiaohong Guan. Characterization and potential diagnostic application of monoclonal antibodies specific to rabies virus[J]. The Journal of Biomedical Research, 2010, 24(5): 395-403. DOI: 10.1016/S1674-8301(10)60053-X
    [9]Chen Tao, Li Dan, Fuya ling, Gongzi Peng. In vivo and in vitro effects of QHF combined with chemotherapy on hepatocellular carcinoma[J]. The Journal of Biomedical Research, 2010, 24(2): 161-168.
    [10]Daozhen Chen, Qiusha Tang, Wenqun Xue, Jingying Xiang, Li Zhang, Xinru Wang. The preparation and characterization of folate-conjugated human serum albumin magnetic cisplatin nanoparticles[J]. The Journal of Biomedical Research, 2010, 24(1): 26-32.

  • Cited by

    Periodical cited type(9)

    1. Nasimi Shad A, Moghbeli M. Integrins as the pivotal regulators of cisplatin response in tumor cells. Cell Commun Signal, 2024, 22(1): 265. DOI:10.1186/s12964-024-01648-0
    2. Li J, Peng L, Chen Q, et al. Integrin β1 in Pancreatic Cancer: Expressions, Functions, and Clinical Implications. Cancers (Basel), 2022, 14(14): 3377. DOI:10.3390/cancers14143377
    3. Dötzer K, Schlüter F, Koch FEV, et al. Integrin α2β1 Represents a Prognostic and Predictive Biomarker in Primary Ovarian Cancer. Biomedicines, 2021, 9(3): 289. DOI:10.3390/biomedicines9030289
    4. Khine HEE, Ecoy GAU, Roytrakul S, et al. Chemosensitizing activity of peptide from Lentinus squarrosulus (Mont.) on cisplatin-induced apoptosis in human lung cancer cells. Sci Rep, 2021, 11(1): 4060. DOI:10.1038/s41598-021-83606-1
    5. Moreira AM, Pereira J, Melo S, et al. The Extracellular Matrix: An Accomplice in Gastric Cancer Development and Progression. Cells, 2020, 9(2): 394. DOI:10.3390/cells9020394
    6. Haeger A, Alexander S, Vullings M, et al. Collective cancer invasion forms an integrin-dependent radioresistant niche. J Exp Med, 2020, 217(1): e20181184. DOI:10.1084/jem.20181184
    7. Yang XG, Zhu LC, Wang YJ, et al. Current Advance of Therapeutic Agents in Clinical Trials Potentially Targeting Tumor Plasticity. Front Oncol, 2019, 9: 887. DOI:10.3389/fonc.2019.00887
    8. Manini I, Ruaro ME, Sgarra R, et al. Semaphorin-7A on Exosomes: A Promigratory Signal in the Glioma Microenvironment. Cancers (Basel), 2019, 11(6): 758. DOI:10.3390/cancers11060758
    9. Raab-Westphal S, Marshall JF, Goodman SL. Integrins as Therapeutic Targets: Successes and Cancers. Cancers (Basel), 2017, 9(9): 110. DOI:10.3390/cancers9090110

    Other cited types(0)

Catalog

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (3229) PDF downloads (460) Cited by(9)
    Related

    ©2023 by the Editorial Department of the Journals of Nanjing Medical University. All rights reserved.   苏ICP备05071376号-5

    Supported by: Beijing Renhe Information Technology Co., Ltd. E-mail: info@rhhz.net  Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return